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Abstract: 
Doxorubicin has long been used clinically to treat a variety of cancers. 
Unfortunately, its success is limited due to its cardiotoxic side effects, restricting the 
cumulative dose that can be given to patients. It is known that the enzyme carbonyl 
reductase 1 (Cbrl) metabolizes this cancer drug in vivo, leading to the production of its 
toxic alcohol metabolite, doxorubicinol. A previous study has indicated that decreasing 
the expression level of carbonyl reductase 1 in male Cbr 1 +I- mice provided them with 
significant protection from doxorubicin-induced cardiotoxicity when compared to their 
wild type littermates. With the intent to identify whether the protection conferred by 
knocking out one copy of Cbr 1 persists in a more diverse population, this subsequent 
study expanded the previous one to include female mice as well as mice of different 
genetic backgrounds. It was discovered that the protective effect conferred by a null Cbr 1 
allele is no longer present, that females survive significantly longer than males, and that 
survival is no longer significantly associated with cardiotoxicity. Western blotting, 
subclinical pathogen analysis, histology, and pedigree analysis were performed in an 
effort to discover an explanation for the unexpected results. It is believed that alternate 
acute toxicity such as leukopenia was responsible for mouse death, whereas such factors 
are controlled in human clinical trials. In the event that decreased Cbr 1 levels provide 
significant cardiac protection, a Cbrl inhibitor could be created to be taken 
simultaneously with doxorubicin. 
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Introduction: 
Doxorubicin, a common chemotherapy drug, has been successfully used in clinics 
since the late 1960s (Arcamone et al., 1969). Originally isolated from the bacteria 
Streptomyces peucetius var. caesius, doxorubicin shares many structural similarities with 
its sister drug, daunorubicin, as well as other drugs in the class of anthracyclines 
(Arcamone et al., 1969; Gharib & Burnett, 2002; Minotti et al. , 2004). Because of 
doxorubicin's ability to inhibit both cellular metabolism and replication, it is useful in 
treating both solid tumors, such as breast cancer, and hematopoetic tumors, such as 
leukemia (Wojatacki et al., 2000). Doxorubicin works to destroy cancer cells by 
preventing DNA replication through intercalation and inhibition oftopoisomerase II, and 
by damaging cellular membranes through the creation of free radicals (Kuffel et al., 
1992; Swain et al., 2003; Horenstein et al. , 2000; Singal & Iliskovic, 1998; Minotti et al., 
2004). It is also thought to be involved in iron chelation (Gharib & Burnett, 2002). 
Although doxorubicin causes many temporary side effects such as leukopenia, 
nausea, and diarrhea, it is most notorious for its dangerous and often chronic side effect 
of cardiotoxicity (Onda et al., 2004; Passardi et al., 2006; Popov et al., 2000). Clinically, 
cardiotoxicity manifests itself in three stages: acute, early onset, and late onset. Acute 
cardiotoxicity, occuring within weeks of the treatment, is the least serious of the 
cardiotoxicities and is rarely fatal. In contrast, both early and late onset cardiotoxicity are 
serious medical concerns, often leading to congestive heart failure or decreased heart 
function. Early onset cardiotoxicity is defined as occurring between months and one year 
of treatment, and late onset as toxicity appearing after the first year post treatment 
(Gharib & Burnett, 2002). Cardiotoxic symptoms affect a significant portion of the 
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population, causing cardiac related deaths in just under 3% of patients within the first 
year of treatment and severe cardiac dysfunction in up to 60% of patients overall (Gharib 
& Burnett, 2002; Olson et al., 1988). 
Although the likelihood of doxorubicin induced cardiotoxicity is proportional to 
the total dose given, methods such as smaller doses over longer periods of time show a 
moderate decrease in risk (Singal & Iliskovic, 1998; Gharib & Burnett, 2002; Swain et 
al., 2003; Lipshultz et al., 1995). The most common protective measure taken currently in 
clinics is to limit the maximum dosage of doxorubicin to 550mg/m2, thus confining the 
risk of congestive heart failure to approximately 7% (Gharib & Burnett, 2002; Singal & 
Iliskovic, 1998; Mordente et al., 2003). Higher doses of doxorubicin show a drastic jump 
in cardiotoxicity, although the effects vary significantly from patient to patient (Gharib & 
Burnett, 2002; Singal & Iliskovic, 1998). Other protective measures include effectively 
lowering cumulative dosage by incorporating doxorubicin into a multiple drug treatment 
often including antioxidants to limit free radical damage (Singal & Iliskovic, 1998; 
Horenstein et al., 2000; Khan et al., 2005). Although these measures have been 
moderately effective, none of them have sufficiently ameliorated the cardiotoxicity 
(Horenstein et al. , 2000). 
Beyond drug treatment regimes, several other factors are known to influence the 
rate of survival of patients treated with doxorubicin. Patients exhibiting previous heart 
conditions have an increased risk for congestive heart failure, as well as patients whose 
cardiac tissue has been previously damaged by radiation (Gharib & Burnett, 2002). 
Patients under the age of 4 and over the age of 65 also have a significantly increased risk 
(Gharib & Burnett, 2002; Li & Gwilt, 2003). Perhaps most surprising is the statistic that 
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males have a decreased risk of cardiotoxicity when compared to their female 
counterparts, even during childhood treatment (Gharib & Burnett, 2002; Lipshultz et al. , 
1995; Minotti et al., 2004). This may be due in part to the stage ofthe cancer being 
treated, as well as the relatively large sample of females studied and the smaller 
proportion of males (Swain et al., 2003). 
Many doxorubicin derivatives have been developed to decrease cardiotoxicity 
including carminomycin, detrorubicin, esorubicin, marcellomycin, quelamycin, and 
rodorubicin (Singal & Iliskovic, 1998). All ofthese attempts have been short lived, 
however, due to their decreased efficacy or failure to decrease cardiotoxicity (Singal & 
Iliskovic, 1998; Gharib & Burnett, 2002). Epirubicin, an epimer of doxorubicin, was 
approved for use as a less cardiotoxic alternative, but later reports showed it too had 
decreased efficacy and showed no improvement in cardiotoxicity after a period of five 
years (Swain et al., 2003; Gharib & Burnett, 2002). Dexrazoxane, a drug used to protect 
the heart by chelating iron, was also given in conjunction with doxorubicin for a time but 
later discouraged because it decreased anti-tumor efficacy (Gharib & Burnett, 2002). 
Ultimately, doxorubicin remains the most effective drug in its ability to destroy multiple 
tumor types. 
Fig. 1 Doxorubicin 
(Olson, L. personal 
communication) 
0 OH OH 
Fig. 2 Doxorubicinol 
(Olson, L. personal 
communication) 
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In exploring the cardiotoxic mechanisms of doxorubicin (Fig. 1) it was discovered 
that the alcohol metabolite of doxorubicin, doxorubicinol (Fig. 2), was predominantly 
responsible for damaging the heart (Olson et al. , 1988; Kuffel et al., 1992; Mordente et 
al., 2003). In experiments bathing rabbit heart tissue in doxorubicin or doxorubicinol, 
doxorubicin was found to have little effect on systolic or diastolic cardiac function 
whereas doxorubicinol was found to severely decrease both (Olson et al., 1988). These 
observations also held true at the cellular level, where doxorubicinol was found to 
decrease the function of cardiac calcium, sodium, and potassium pumps responsible for 
contraction as well as the proton pump responsible for oxidative phosphorylation (Olson 
et al., 1988). 
Furthermore, doxorubicin was found to be more effective than doxorubicinol at 
killing tumor cells in vitro. When human leukemia and glioblastoma derived cancer cells 
were treated with doxorubicin, 50% inhibition of growth was observed at concentrations 
of less than 1 0 ng/mL, in comparison to doxorubicinol which required concentrations of 
between 168 and 220 ng/mL to achieve the same inhibition (Kuffel et al. , 1992). 
Doxorubicin was also more effective at breaking single stranded DNA, producing a 20 
fold increase as measured by alkaline elution when compared to the same drug 
concentration for doxorubicinol (Kuffel et al. , 1992). The impact of identifying the cause 
of cardiotoxicity as independent from the chemotherapeutic agent was revolutionary in 
that it supported the development of cardioprotective measures that would not interfere 
with chemotherapy. 
Studies looking at the mechanism of doxorubicin-induced cardiotoxicity revealed 
Carbonyl reductase 1 as the reducing enzyme responsible for converting doxorubicin into 
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doxorubicinol in vivo (Mordente et al., 2003; Forrest et al., 2000; Olson et al. , 2003). 
Carbonyl reductase 1 is highly conserved between species and can be found within the 
genome on human chromosome 21 (CBRJ) and mouse chromosome 16 (Cbrl) (Miura et 
al. , 2008; Olson et al. , 2003). A cytoplasmic enzyme responsible for the metabolism of 
prostaglandins and steroids through reducing carbonyl groups, Cbrl is classified under 
the larger category of short-chain dehydrogenase/ reductases (Miura et al. , 2008). The 
expression ofCbr1 occurs in almost all body tissues with higher expression present in 
both the liver and kidneys, and is thought to play an important role in metabolism as mice 
missing both copies of the gene are fetal lethal (Miura et al. , 2008; Olson et al. , 2003). 
In 2000, a transgenic mouse was created with overexpression of the CBR1 
enzyme in the heart. CBR1 overexpressing mice, as well as their wild type(+/+) 
littermates, were treated with doxorubicin in doses meant to mimic both acute and 
chronic cardiotoxicity and monitored for survival as well as for levels of doxorubicinol 
and cardiotoxicity. Mice overexpressing CBR1 showed increased conversion of 
doxorubicin to doxorubicinol over the short term, although the difference decreased over 
time. As would be expected from the increased levels of doxorubicinol, CBR1 
overexpressing mice also exhibited increased cardiac damage when measured by 
histology as well as ECG telemetry. Finally, the survival of mice with heightened levels 
ofCBR1 was approximately 5 weeks as compared to the 12 week survival rate of wild 
type mice (Forrest et al. , 2000). 
Based upon the success of correlating increased Cbr1 expression to increased 
cardiotoxicity, Olson et al. performed similar experiments in 2003 with mice lacking one 
copy of the Cbr I gene. Unlike the heart-targeted expression in Forrest' s mice, the 
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Cbri+/- mice used in this experiment had lower expression levels ofCbrl throughout the 
body, as well as only 38% of the wild type cardiac expression when measured by western 
blotting. Cbri+I- mice and their wild type littermates were given a large dose of20 
mg/kg doxorubicin and monitored for cardiotoxicity and survival for 18 days (Olson et 
al., 2003). 
Cbri+I- mice exhibited increased survival when compared to their wild type 
littermates with 82% of Cbr I +I- mice and only 8% of the wild mice surviving to the full 
18 days. This was supported by the 1 0% more body weight lost in wild type mice than in 
Cbri+I- mice. Cardiotoxicity was correlated to early death via histology and 
echocardiograms, showing increased cell necrosis and decreased heart function in wild 
type mice. In contrast, the Cbr I +I- mice presented cardiac tissue almost as healthy as 
saline treated control mice for both tests (Olson et al., 2003). 
This experiment, performed at Johns Hopkins, presented promising results for the 
inhibition of Cbrl as a way to decrease cardiotoxicity. Although the sample size was 
small with only twenty-two 129SVE mice, the significance of the results led to the 
expansion ofthe project at the University of Redlands between 2003 and 2006. This 
expanded study followed the protocol of the earlier study, but examined a larger sample 
size of 166 mice including males and females. Mice were maintained on the original 
129SVE genetic background as well as C57BL6/J, FVB, and C57BL6/JFVB 
backgrounds (Schwartz, 2005; Lechuga, 2006). By varying the genetic background, this 
project sought to strengthen the previous results as observed phenotype would not be tied 
to the genotype of one mouse strain. Utilizing different mouse strains varies underlying 
genetic strain novelties such as modifier genes, which are known to play a significant role 
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in various phenotypes (Nadeau, 2001). Due to facility limitations, echocardiograms were 
not performed as in the previous study, and mice were maintained in a non-virus 
antibody-free colony (Schwartz, 2005; Lechuga, 2006). Studying how different sexes and 
backgrounds of Cbr 1+/- mice react to doxorubicin should give insight into the potential 
success of inhibiting Cbr 1 activity temporarily as a method of cardiotoxic protection 
clinically. 
With the completion of the data collection in 2006, the results have now been 
analyzed to identify whether or not the protective effect conferred by a loss of one copy 
of the Cbr 1 gene is preserved across varying sexes, backgrounds, and laboratories. To 
interpret the collected data, survival, Cbrl expression levels, and cardiotoxicity were 
compared between the mice at the Johns Hopkins colony and the University of Redlands 
colony. To control for other possible interfering factors between the two colonies, mouse 
lines were analyzed for possible genetic mutations and the colony was monitored for 
subclinical pathogens. 
Methods: 
Statistical Analysis 
Statistical analysis was performed comparing the survival of the mice studied at 
the University of Redlands to the mice previously studied at Johns Hopkins under the 
supervision of the resident statistician. Multiple graphical and numerical approaches were 
used, including Kaplan-Meyer survival curves, trellis graphs, classification and 
regression trees (CART), and Logrank tests to present an accurate comparison. Logrank 
tests were chosen for the equal weight given to each death time relative to the 
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population' s overall survival. Independent variables included animal sex, background, 
genotype, researcher, date of birth, and cause of death (euthanasia or found dead). All of 
these factors were compared using survival time and controlled by the baseline survival 
of saline treated mice. Wild type mice also acted as controls to their Cbr 1 +I- littermates. 
Based upon this data the survival times of the genotypes, sexes, backgrounds, and 
locations were compared, allowing for the identification of groups with particularly high 
or low survival. Logrank tests were utilized to give equal weight to each death. 
Survival Pedigree 
To control for the possibility of a genetic mutation altering survival rates, the 
colony was organized into a relational diagram and analyzed to identify any possible 
survival patterns. Mating records collected between 2003 and 2006 were collated and the 
mice graphically displayed to visually represent relationships within the study group. 
Mouse lineage was traced through the father as multiple female mice per cage made 
maternal descent difficult and often impossible to trace. Fortunately, most mating females 
were paired with female siblings from the same litter to reduce this source of error. Each 
mouse responsible for fathering studied offspring was given a number for ease of 
identification based upon his paternal lineage. For example, the first male mouse to breed 
in the colony was numbered mouse 1. His second male offspring to mate was numbered 
21, and mouse 21's third male offspring to mate was numbered 321. Thus the numbering 
system for this last mouse can be read as the third male born of the second male born of 
the first male. 
Mice were also labeled for survival relative to the other mice of their genotype so 
that other factors could be considered. The median survival time as calculated by Kaplan 
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Meyer analysis of both genotypic samples was buffered by a day before and after to form 
a three day expected survival time for each respective group. Survival times falling 
before this period were categorized as earlier than expected and survival times after this 
period as later than expected. Based upon these categories it was possible to identify mice 
falling above or below the expected survival rate in both genotypes and thus identify any 
possible trends in decreased survival in a relational setting. Litters were numbered in 
order from the earliest birth date to the latest. 
Statistically, mice were categorized through classification and regression trees to 
identify survival factors such as sex and background as well as lineage. Factors identified 
through this method were reconfirmed numerically with other analytical methods such as 
Logrank tests. If one or more lineages showed a change in survival as compared to the 
other groups, it was assumed that a genetic mutation had potentially occurred and had 
been passed down through this line of mice. 
Western Blotting 
To compare Cbrl expression levels of mice studied at the University of Redlands 
and Johns Hopkins, western blotting was performed. Wild type and Cbrl+/- mice ofboth 
sexes from C57B16/J and 129SVE backgrounds were sacrificed by cervical dislocation to 
allow for immediate removal of organs. Brain, spleen, kidney, lung, liver, muscle, and 
heart were dissected out and immediately placed upon ice for preservation, where they 
were kept until they were homogenized by mortar and pestal in liquid nitrogen or a 
dounce depending on tissue consistency and trial runs. One ml ofNP40 buffer (137mM 
NaCl, 2mM EDTA, 10% glycerol, 1% NP40, and 20mM Tris in water) spiked with 1:10 
dilution of protease inhibitor cocktail (Sigma, St. Louis, Missouri) was added to the 
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homogenized tissue to protect the protein from degradation. Tissue was then centrifuged 
at 1100 rpm for 10 minutes and supernatant was frozen at -20°C. Protein concentration 
was measured with a Bradford assay as run on a Thermo Electron Corporation Multiskan 
MCC (Thermo Electron Corporation, Vantaa, Finland), and the resulting concentrations 
converted through a standard curve as performed by Paul and Sata (Paul, 2007; Sata, 
2007). 
Sodium dodecylsulfate polyacrylimide gel electrophoresis (SDS PAGE) was 
normalized with 10 1-1-g protein per well as calculated from the Bradford assay. Protein 
samples were combined with NP40 buffer to bring the solution to 5 ~-tl. Five ~-tl Laemmeli 
sample buffer (LSB) (BioRad, Hercules, California) with 5% betamercaptoethanol was 
then added to bring the solution to 10 ~-tl. Proteins were then denatured by a 5 minute 
95°C incubation period. Samples were run on a ready-made 12% polyacrylimide gel 
purchased from Biorad (Hercules, California) alongside Color Burst electrophoresis 
marker (Sigma, St. Louis, Missouri). Gels were buffered in 1x SDS-PAGE running buffer 
(2.5mM Tris, 19.2mM glycine, and 0.01% SDS in water) and run at 200 Volts for 30 
minutes. 
Gels were then blotted to Ready Gel™ 0.45~-tm nitrocellulose membranes 
(BioRad, Hercules, CA) by a blotting apparatus (Owl Separation Systems, Rochester, 
New York) run constantly at 5 volts for one hour as opposed to the conventional100-120 
amps for 1.5-2 hours due to equipment limitations. Membranes were stained with a 
Ponceau solution (1.3mM Ponceau stain and 25% Acetic acid in water) for 5 minutes and 
rinsed with di water to remove excess stain. Band presence verified protein extraction 
and identified any discrepancies in protein levels before the membrane was destained 
11 
with 0.1M NaOH for one minute. Membranes were blocked overnight in Tris-buffered 
saline (TBS) containing 0.1% Tween and 5% w/v non fat dried milk. The membranes 
then underwent five rinses in 0.1% TBS with 0.1% Tween: two briefrinses, one 15 
minute rinse, and two 5 minute rinses. Membranes were probed by rocking for 1 hour 
with rabbit IgG anti-HCbr monoclonal primary antibody generously donated by Dr. Akira 
Hara at a 1:10,000 dilution in TBS with 0.1% Tween. Membranes were rewashed 
following the procedure stated above, and then probed by rocking for 1 hour with 
horseradish peroxidase-linked anti-rabbit immunoglobulin from donkey (GE Healthcare, 
Buckinghamshire, UK). 
Membranes were washed a third time following the above protocol and finally 
visualized via GE Healthcare's Amersham ECL Plus western blotting detection system 
(GE Healthcare, Buckinghamshire, UK). A ratio of 40:1 of solution A and B was mixed 
together and the membrane was incubated in the solution for 5 minutes before being 
exposed to Ampersham Hyperfilm TM high performance ECL chemiluminescence film 
(GE Healthcare, Buckinghamshire, UK). Different exposures were taken for each 
membrane to ensure the clearest image was obtained. Film was developed in a dark room 
by bathing it in developing solution for 5 minutes, stop solution for 30 seconds, and 
fixative solution for 5 minutes before being rinsed thoroughly with water and allowed to 
dry. Membranes were then re-probed with a control anti-a-tubulin mouse primary 
antibody (Calbiochem, San Diego, California) and horseradish peroxidase-linked anti-
mouse immunoglobulin from sheep (GE healthcare, Buckinghamshire, UK) as a 
secondary antibody. The same washing, probing, and visualizing procedure was followed 
as with the Cbr 1 western blotting. 
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Developed film was scanned into a digital format and analyzed by optical 
densitometry using the Labworks (Novato, California) program. Each band was 
compared to blank background on the film to control for background coloration. 
Measurements were made using total density as determined by a standard optical curve in 
OD units. Tubulin banding was quantified to identify any loading inequalities and each 
Cbrl band' s intensity was divided by its relative tubulin control to normalize for any 
discrepancies. The Cbrl/tubulin ratios were then converted to percents in order to 
determine relative expression levels between genotype, sex, and background. The relative 
expression levels obtained from western blotting were compared to the previous western 
blot data recorded at Johns Hopkins. 
Subclinical Pathogens 
To identify or eliminate health differences as a factor in survival rates, subclinical 
pathogens were tested for by the project's veterinarian. This aspect was particularly 
important to comparing the colonies as the colony at the University of Redlands was not 
maintained in a pathogen free environment as with Johns Hopkins. Sentinel mice from 
the colony were exposed to the same environmental factors and potential pathogens as 
the other mice. Bedding samples from each of the study mice were taken weekly and 
added to the cage of the sentinel mice, bringing them in contact with pathogens that 
might not have spread throughout the whole colony. Mice were then sacrificed and 
analyzed by Lorna Linda University for any pathogens that had infected the colony. 
Cardiac Histology 
To ensure that the deaths of mice during the study were caused by cardiotoxicity 
and not other factors, histology was performed on preserved hearts to relate 
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cardiotoxicity to time to death. A direct association was expected as was observed at 
Johns Hopkins with healthy hearts found in mice with longer survival times. To begin the 
study, a pilot group was chosen containing the longest and shortest survival times of wild 
type and Cbr 1+/-, male and female mice for a total of 8 mice. The researcher quantifying 
cardiotoxicity was blinded to all of these factors and the resulting comparisons were 
informative as to whether extreme survival was correlated to heart function. 
Hearts removed at the time of death or immediately after mice were found dead 
were rinsed with 1x phosphate buffered saline (PBS), fixed with 10% phosphate buffered 
formalin overnight, washed again with 1x PBS, and finally stored in 0.02% Sodium 
Azide in 1 x PBS at 4 °C (Lechuga, 2006). These hearts were trimmed of their excess fat 
or blood vessels and weighed to identify possible cardiomegaly. Weighed hearts were 
then cut so as to separate the ventricles from the atria, and the atria were replaced in 1 x 
PBS with 0.02% sodium azide at 4°C. 
The ventricles were then dehydrated in a series of incubations in 50, 70, and 95% 
ethanol for 1 hour each. Two incubations of 100% pure ethanol followed, lasting 30 
minutes each, completing the dehydration process and making way for infiltration with 
paraffin. A 15 minute incubation in a 1:1 dilution of Histoclear II (National Diagnostics, 
Atlanta, Georgia) in 100% pure ethanol acted as a bridge between paraffin and ethanol, 
and was followed by a 15 minute incubation in Histoclear II alone. Transition to paraffin 
followed with a 15 minute incubation in a 1: 1 solution of Histoclear II and melted 
Paraplast® Plus tissue embedding paraffin (Fischerbrand™, Houston, Texas) at 60°C. 
Two 30 minute incubations in paraffin at 60°C ensured complete infiltration of wax into 
the cardiac tissue. Finally, the hearts were embedded, atria end down, in wax forms. 
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Embedded hearts were then sectioned by a Leica® microtome (GmbH, 
Darmstadt, Germany) into 5)lm sections (approximately the width of one cell) and 
incubated on wet, albumin-covered slides at approximately 40°C for 24 hours to allow 
tissue to spread. Embedded hearts were refrigerated approximately 24 hours ahead of 
sectioning to provide maximal rigidity of the sections and minimal tissue folding. Ten 
slides were created per mouse with approximately 6-8 sections per slide. Wax was then 
removed from slides with two baths of 4 minutes each in 1 00% mixed xylenes followed 
by rehydration via ten dips each in 100%, 95%, and 70% ethanol. Four minutes of 
incubation under running water completed the rehydration. Next, the tissue was stained 
for 2 minutes with acidic hematoxylin Gill2x (Protocol®, Kalamazoo, Missouri) which 
interacted with the nucleic acids and stained the nuclei a dark purple. Hematoxylin was 
first filtered via a 0.50 mm filter (Nalgene®, Rochester, New York) to remove any 
crystallized solution that might have interfered with image analysis. Excess stain was 
removed with another 4 minute incubation under running water. Next, tissue was stained 
for 1 minute with basic eosin (0.7mM Eosin Y, 70% ethanol, and 0.25% glacial acetic 
acid) meant to interact with the basic cytoplasmic proteins, thus staining the cytoplasm 
pink. Tissue was immediately re-dehydrated with a series of ethanol rinses involving one 
dip in 70% ethanol and 5 dips in 95% ethanol. To finalize the dehydration, five more 
baths at 2 minutes each were completed: twice in 1 00% pure ethanol, once in a 1: 1 
solution of pure ethanol and mixed xylenes, and twice in 100% xylenes. Slides were then 
air dried to allow for the evaporation of excess xylenes and finally covered with 
coverslips bound by Permount® toluene solution (Fischer Chemicals, Hatfield, 
Pennsylvania). 
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Stained slides were viewed by an Olympus BX41 light microscope (Olypmus, 
Melville, NY) and images captured through the Microfire program (Optronics, Goleta, 
CA) to look for signs of cardiotoxicity. The best section per slide as determined by a 
captured image at 400x magnification was selected for further analysis to prevent 
adjacent sections with similar tissue from being over counted. These 10 best sections per 
mouse were closely observed for signs of mineralization, necrosis, organization and 
vacuolization at magnifications ranging from 1 OOx to 4000x. A modified Billingham 
scale was used to quantify results, including quantifying the ratio of necrotic cells to the 
number of healthy cells present in each field (Billingham, 1991 ). Direct association was 
expected between survival time and cardiotoxicity. 
Results: 
Comparative statistics to determine relative survival times between colonies: 
Male 129SVE mice at Johns Hopkins were given a bolus i.p. injection of20 
mg/kg with 1 mg/mL doxorubicin. They were then observed for a period of 18 days and 
examined for signs of cardiotoxicity. The same study was performed at the University of 
Redlands and expanded to include the 129SVE, 129FVB, C57BL6/J, and C57BL6/J FVB 
backgrounds as well as mice of both sexes (Table 1). Females accounted for 44% of the 
population and males for 56%. Mice were distributed into the study groups as breeding 
productivity permitted, leading to a slightly lower 129FVB sample population as 
compared to the larger 129SVE and C57BL6/J populations (Table 1). The 7 Cbrl +/- and 
17 wild type (WT) saline treated control mice survived the full length of the 19 day study 
and experienced no adverse affects. 
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Kaplan Meyer and Logrank analysis revealed significant differences between 
similar genotypes in the doxorubicin treated mice at Johns Hopkins and the University of 
Redlands (Fig. 3) (Olson et al., 2003). This trend persisted even when only male mice of 
the 129SVE background were compared to mimic the original study (data not shown). 
Whereas the study conducted at Johns Hopkins showed a significant increase in survival 
time with doxorubicin-treated Cbr 1 +I- mice as compared to their WT counterparts, 
survival times between Cbrl+/- and WT mice at the University of Redlands were not 
statistically different (Fig. 4). Classification and regression tree (CART) analysis revealed 
a previously unidentified sex difference in survival, identifying it as the second most 
important factor after that of doxorubicin vs. saline injection (Fig. 5). Further Kaplan 
Meyer and Logrank analysis confirmed the difference, showing a significant increase 
(p<0.0001) in female survival time compared to males regardless of genotype (Fig. 6). 
This trend remained when comparing mice in individual backgrounds, although females 
in the 129 SVE background exhibited less significant protection and 129 SVE males 
showed a slightly increased protection as compared to the other backgrounds (Fig. 7). 
Average survival time rose slightly from approximately 6 days to 9 days, and then 
decreased to approximately 7 days during the two years over which survival data was 
collected (Fig 8). Other factors, including the researcher performing the injection were 
found to have no significant impact upon the survival of the mouse (data not shown). 
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Genetic !Females !Males 
!Background 
Sunnval Plot 
lfotal 
L ___  _ R Cbrl+/- n=79 
-····· R WTn=87 129SVE 31 135 66 ~ 0.750 ....... JH Cbrl+/- n=II 
..... JHWTn=II 
129FVB ~ 8 13 
IC57BL6/J 27 ~2 59 
C57BL6/J 10 18 ~8 
IF VB 
tfotal r3 ~3 166 
Table 1. Study population demographics: 
background and sex. 129FVB indicates 
F1 generation from one 129SVE and one 
FVB parent. C57BL6/J FVB indicates F1 
generation from one C57Bl6/J and one 
FVB parent. 
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Fig 3. Redlands (R) Cbrl+/- mice exhibit 
lack of doxorubicin protection as compared 
to Johns Hopkins (JH) mice. Confidence 
intervals not shown due to space 
constraints. (p=0.0014, Logrank) 
Fig. 4. No statistical difference is 
observed in survival times between 
Cbrl+/- mice and WT mice at the 
University of Redlands. Bounding lines 
indicate 90% confidence intervals. 
(p =0.0974, Logrank) 
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B6 FVB, 
129 FVB, 
B6 
Male Female 
· 129 SVE 
B6, B6 FVB, 
129 SVE;:::.-.........,~Jl-!ILI........,...___-----=.12 9 FVB 
19.000 
Fig. 5. CART tree of mice treated with doxorubicin and saline. Heights of branches 
indicate relative significance. The point at which the text becomes illegible is where 
factors become insignificant. Numbers at the end of the branches indicate survival time of 
mice following that branch. Treatment type, sex, and background play the most significant 
roles in determining survival time in order from most important to least important. No 
other factors were associated with survival time. 
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Fig. 6. Females exhibit a statistically significant 
increase in survival as compared to males. 
Bounding lines indicate 90% confidence 
intervals. (p=O.OOOO, Logrank) 
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Fig. 7. Male mice show consistently lower survival times than females in 
their respective backgrounds. This trend is weaker in the 129SVE 
background. Black dots indicate median survival time, boxes indicate 
interquartile range (IQR), whiskers indicate the nearest data point within 
the median± 1.5IQR, and blue dots indicate outliers. 
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Fig. 8. Mean survival increased during 
the study period and subsequently 
regressed, with high variation visible 
throughout. Points indicate mean survival 
for all mice born on that date. Trend 
curve calculated by the Loess method. 
Bar graph: inner line indicates median, 
box indicates interquartile range, and 
whiskers indicate the nearest data point 
within the median±1.5IQR. 
Assessment of possible genetic mutations in colony: 
Based upon the differences in survival between the University of Redlands and 
Johns Hopkins colonies, it was hypothesized that a mutation had occurred which altered 
survival time. To test this, the study population and their direct ancestors were compiled 
into a pedigree totaling 211 mice and up to six generations (Fig. 1 0). Due to limited 
colony facilities and population availability, inbreeding was present and could have 
played an unknown role in compounding the effect of genetic mutations. Statistical 
analysis showed the median survival day ofthe Cbrl+/- mice to be 6 days as compared to 
7 days in WT mice. Accordingly, Cbrl+l- mice surviving 0-4 days were considered to 
have relatively low survival, 5-7 days average survival, and 8-19 relatively high survival 
(Fig.9). WT mice surviving 0-5 days were considered to have relatively low survival, 6-8 
days average survival, and 9-19 days relatively high survival (Fig. 9). It was expected 
that if mutations had occurred within the colony, that survival trends could be isolated to 
one lineage, with the offspring of one mouse (in whom the mutation arose) exhibiting 
decreased survival as compared to other mice sharing their sex, background, and 
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genotype. Thus, we would expect the pedigree to look patchy, with sections of primarily 
"red" mice, and sections of primarily "green" mice indicating that certain parents were 
producing mice predisposed to shorter or longer survival than the rest of the colony. 
Visual inspection of the pedigree using this method revealed no clear genetically linked 
trend, with the red, green, and yellow mice fairly evenly distributed throughout the 
pedigree (data not shown). Box plots comparing father to survival time also showed no 
clear relationship (Fig. 11 ). 
Cbr1+/-
WT 
0 1 2 3 4 5 7 8 9 10 11 12 13 14 15 16 17 18 19 
I I I i-1 1 __ , __ , 
,-J I I --~'--~-l 
Fig. 9. Mean survival ofthe Cbrl+/- mice was 6 days as compared to 7 in 
WT mice out of 19 days. This color coding method was used to code the 
following lineage chart, looking for patterns. 
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Fig. 10. Pedigree of study mice and 
their direct ancestors. Inbreeding is 
evident. Red Cbr 1 indicates parent 
who passed on the null allele. Litters 
are numbered by date of birth. 
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Fig. 11 No significant difference is evident between the fathers and 
the survival time of the offspring. Inner lines indicate median survival 
time. Notched bars indicate the median± (1.57xiQR)/--Jn , and 
whiskers indicate the nearest data point within the median ±1.5IQR. 
If one father ' s offspring had exhibited notched bars distinct from the 
others, it would have supported the theory that a genetic mutation had 
occurred. (This was not the case.) 
Western blotting analysis to determine protein expression: 
It was hypothesized that Cbrl expression levels would differ between the 
University of Redlands and Johns Hopkins, causing a decrease in cardio-protection and 
survival time despite the genetic loss of one copy ofthe CBR1 gene. Western blotting 
was performed on homogenized tissue born during September, 2006 to quantify Cbrl 
protein levels and tubulin control levels (Fig. 12). Optical intensity values of the Cbrl 
bands were divided by the tubulin loading control bands to control for any unevenness in 
loading. WT male mice were set as 100% expression for the organ in question and the 
equation ((Cbr+/- expression/ WT expression)*100) was used to determine the relative 
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percent of expression in Cbr1+/- mice as compared to the WT mice. Thus a value of 
greater than 1 00% indicated that the Cbr 1 +I- mice had higher expression levels than the 
WT mice, and a value of less than 100% indicated that Cbr1+/- mice had lower 
expression levels than the WT mice. Comparing just 129SVE male mice from the 
University of Redlands to the 129SVE male mice of Johns Hopkins was difficult due to 
technical difficulties and the small sample size of one. At the University of Redlands, 
Cbrl expression in 129SVE males in the liver and kidney were confounded by dark 
backgrounds and extreme expression in other mice, respectively. Thus it was only 
possible to compare heart expression between the two colonies. The heart of the male 
129SVE Cbr1+/- mouse at the University ofRedlands expressed 63.8% of the WT 
129SVE male. 
Due to the small sample size, the results were expanded to include male and 
female mice of the 129SVE and C57BL6/J backgrounds. The optical density divided by 
tubulin values ofthe mice were averaged within the WT and Cbr1+/- groups, and the WT 
mice were set as 100% of organ Cbrl expression. The formula ((Avg. Cbr1+/-
expressionl A vg. WT expression)* 1 00) was used to determine the relative percent of 
expression in Cbr1+1- mice as compared to the WT mice. Comparing the three 
previously studied organs (heart, kidney, and liver), Cbr 1+1- mice were found to express 
37.1%, 18.2%, and 74.7% ofWT mice, respectively (Fig. 12). These values are much 
more consistent with the findings of Olson et al. (2003), which found that, using the same 
formula, Cbr1+/- mice expressed 38%, 30%, and 49% ofthe WT mice in the heart, 
kidney, and liver, respectively (Olson et al. , 2003). 
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Four other organs that had not been studied previously: the brain, muscle, spleen, 
and lung, were also measured for their Cbr1 expression levels within each organ (Fig. 
12). Using the aforementioned formula to compare Cbr I +I- and WT mice, Cbr 1 +/- mice 
were found to express 225%, 166.5%, and 76.9% of their WT counterparts in the brain, 
muscle, and spleen, respectively (Fig. 12). Lung expression of Cbr1 was not detectible in 
either Cbr1 +/-or WT mice, and could not be analyzed. 
As this study was also intended to elucidate any sex differences in Cbrl 
expression, ·the results were again analyzed to compare female and male expression levels 
both for the previously studied and newly introduced organs (Fig. 12). The optical 
density divided by tubulin values were averaged within each group of male and female 
mice, and the female mice were set as 100% of organ Cbrl expression. The formula 
((Avg. male expression/ Avg. female expression)*100) was used to determine the relative 
percent of expression in male mice as compared to female mice. In the heart, liver, brain, 
muscle, and spleen, males expressed 111.2%, 58.7%, 27.9%, 67.8%, and 111.4% of 
female expression levels, respectively (Fig. 12). In the kidney, male expression levels 
were exceptionally low, with males expressing 0.16% as compared to females. 
In all organs, background differences were negligible (data not shown). Cbrl 
bands were visible between the expected 30 and 45 kDa marker bands, conforming to the 
previously recorded 30.6 kDa protein weight for Cbrl. Significant bands were also 
observed in the 100 kDa range for the heart, muscle, spleen, and kidney. In all cases 
Ponceau staining was reasonably even and correlated to the tubulin control western blots 
(data not shown). 
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A 
Cbrl +I+ +I- +I+ +/- +I+ +I-
-----
Background 129SVE 86 129SVE 86 129SVE 86 129SVE 86 129SVE 86 129SVE B6 
Sex M F M F M F M F M F M F M F M F MFMFM FMF 
Cbrl 
Tub 
B 
Cbrl 
~r-------~------------~--------~--------~ 
Heart (Cbr/+/-37.1%ofWT, Kidney (Cbrl+/-74.7%ofWT, 
Males 111.2% of Females) Males 0.16% of Females) 
+I+ +I- +I+ +I-
Liver (Cbrl+/- 18.2% ofWT, 
Males 58.7% of Females) 
+I+ +I-
Background 129SVE 86 129SVE 86 129SVE B6 129SVE 86 129SVE B6 129SVE B6 
Sex 
Cbrl 
Brain (Cbr/+1- 225.8%ofWT, 
Males 27.9% of Females) 
Muscle (Cbrl+l- 166.9% ofWT, 
Males 67.8% of Females) 
M F M F M F M F 
Spleen (Cbrl+l- 76.9% ofWT, 
Males 111.4% of Females) 
Fig. 12. Western blotting confirmed decreased Cbrl expression levels in the hearts, 
kidneys and livers of Cbr 1+1- mice (A). Cbrl expression levels in the spleens of Cbr 1+1-
mice also decreased, while the brains and muscles of Cbr 1 +I- mice expressed increased 
Cbrl levels as compared to their WT counterparts (B). Organ expression levels differed 
significantly between sexes. B6 is the abbreviation for C57BL6/J. M indicates male and F 
indicates female. Expression percentages were calculated by dividing average Cbr 1 +/-
expression into average WT expression, and average male expression into average Female 
expressiOn. 
Assesment of subclinical pathogens present in colony: 
Based upon the differences in survival between the University of Redlands and 
Johns Hopkins colonies, it was hypothesized that a subclinical pathogen might have 
infected the colony and increased the likelihood of early death. Two sentinel mice from 
the colony were exposed to bedding from all of the other mice in the colony from 
October Iih, 2006 until November 9th, 2006, and then sacrificed to identify any 
subclinical pathogens present in the colony (Schlobohm, personal communication). Mice 
were tested at Lorna Linda University for general anomalies found upon necroscopy, as 
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well as the Mouse Hepatitis Virus (MHV), Minute Virus of Mice (MVM), NS-1, Mouse 
Parvovirus (MPV), Mycoplasma pulmonis, Mycoplasma arthritidis, Theiler's Murine 
Encephalomyelitis Virus (TMEV), Ectromelia Virus (Mouse Pox), Epizootic Diarrhea of 
Infant Mice (EDIM), pinworms, and mites. Mice were found to have a mild case of 
pinworms, and were subsequently treated with a Fenbendazole diet at 150 ppm on 
alternating weeks (Newco, Rancho Cucamonga, CA) to clear the infection. No other 
irregularities were observed. 
Histologic assessment comparing heart health and survival time: 
Mice treated at Johns Hopkins University showed significant association between 
early death and cardiotoxicity. It was hypothesized that this trend would continue in the 
University ofRedlands colony. The hearts of mice treated with doxorubicin were 
removed postmortem, weighed, and a pilot study performed to quantify histological 
analysis with a modified Billingham scale (Billingham, 1991). Four ofthe study mice 
were found dead, and four of them were euthanized for quality of life issues when they 
showed severe distress or when the study had been completed (Table 2). Heart weights 
ranged between 0.07 and 0.14 grams (Table 2). Male hearts were not significantly larger 
than female hearts (p=0.085 cox regression), with an average of0.12 g and 0.085 g, 
respectively. Mice who died earlier than their matched counterparts had slightly larger 
hearts with an average of 0.11 g and 0.095, respectively, although this could not be 
confirmed with statistical analysis (p=0.28 cox regression). Sample sizes were too small 
to determine if heart size in either the male or female sex had an impact on survival time. 
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Heart health was quantified using a six-factor system based upon the number of 
condensed nuclei, the number of healthy nuclei, the number of undetermined nuclei, the 
number of instances of vacuolization, the number of instances of mineralization, and the 
overall organization on a scale of 1-5 in 0.5 intervals. The organization scale was 
approximated using the following guidelines: 5 being over 90% of the muscle fibers 
clearly delineated and a clear sense of direction and cohesiveness in overall tissue, 4 
being over 70% of muscle fibers clearly delineated and a general sense of direction and 
cohesiveness, 3 being over 50% of the muscle fibers delineated and a general sense of 
direction still identifiable but confounded by wayward segments, 2 being less than half of 
the muscle fibers delineated and a loss of general direction with several segments leading 
different directions and no overall cohesiveness, and 1 being no or almost no individual 
muscle fibers delineated with no cohesiveness and the overall direction characterized by 
waves, gaps, and heavily segmented tissue leading in varying directions. Mineralization 
was ultimately excluded as a viable variable due to a failure in hematoxylin filtration 
which left crystallized stain on the slides. Because of the striking similarity between 
doxorubicin induced mineralization and hematoxylin crystallization, no conclusion could 
be reached isolating one from the other. 
The surveyed hearts varied greatly in their cardiotoxicity levels as quantified by 
the aforementioned scale (Fig. 13). Hearts were observed to generally fall under one of 
three categories: generally cardiotoxic, generally healthy, and a combination of both. 
These last hearts were characterized by patchy areas of abnormally cardiotoxic tissue 
followed by areas of grossly healthy tissue. Patches were not isolated in one ventricle, 
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and were evenly spread throughout the heart from the apex to the upper ventricles. Sex 
and genotype were not significant in determining survival time or heart health (Table 2) 
Comparative analysis confirmed that both measurements of healthy tissue, overall 
organization score and number of healthy nuclei, appeared to be positively associated 
(Fig. 14). Survival was compared to each ofthe heart health factors (with the exception 
being mineralization) using a series of trellis graphs. No significant relationship was 
observed between survival and the number of healthy nuclei present (Fig. 15) or the 
overall organization (Fig. 16). Graphs were generated using both number of healthy and 
necrotic nuclei present per image, as well as percent of healthy and necrotic nuclei per 
image to correct for different whole counts of nuclei per image (data not shown). Neither 
method produced significance, and both seemed to reflect the same trends. 
Fig. 13. No significant association exists between survival time and 
cardiotoxicity. (A) Cardiac tissue from a male mouse that survived to the full 
19 days. Strong fiber organization and healthy nuclei (black arrow) are 
evident. (B) Cardiac tissue from a female mouse that survived to the full19 
days. Extensive cardiotoxicity is represented by necrotic nuclei (red arrow), 
vacuolization (blue arrow), and mineralization (green arrow). Size bar 
indicates 50J.1m. 
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Heart Death Avg. % of 
weight Survival healthy Avg. 
Sex Genotype Time cells STD Organization STD. 
F WT 0.07 g 11 Died 80.58 6.012 4.556 0.4162 
F WT 0.07 g 8 Euth 70.92 8.435 3.528 0.4363 
M WT 0.11 g 19 Euth 67.77 9.700 3.500 0.8101 
M WT 0.14 g 6 Died 71.86 11.044 3.656 0.6762 
F Cbr1+1- 0.09 g 19 Euth 59.18 15.141 2.033 0.8550 
F Cbr1+1- 0.11 g 6 Died 70.86 8.540 3.433 0.6230 
M Cbr1+1- 0.11 g 19 Euth 48.48 14.153 3.250 0.6977 
M Cbr1+1- 0.12 g 6 Died 75.12 11 .721 4.813 0.4031 
Table 2: Demographics and Cardiotoxicity in Pilot Study Mice. STD indicates standard 
deviation. Died indicates that the mouse was found dead. Euth indicates that the mouse was 
euthanized. 
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Fig. 14. Organization and the percent ofhealthy nuclei per image appear 
to be positively associated overall. Black dots indicate median, boxes 
indicate interquartile range, whiskers indicate the nearest data point 
within the median± 1.5IQR, and blue open dots indicate outliers. 
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Fig. 15. No significant association is observed between the number of 
healthy nuclei present and survival time. Black dots indicate median, 
boxes indicate interquartile range, and whiskers indicate the smallest and 
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Fig. 16. No significant relationship is observed between overall 
tissue organization and survival time. Black dots indicate median, 
boxes indicate interquartile range, and whiskers indicate the 
smallest and largest data points within the median± 1.5IQR 
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Discussion: 
Knocking out one copy of the Cbr 1 gene failed to produce the same protective 
results in the University of Redlands mice that were seen in mice following the same 
doxorubicin treatment protocol at Johns Hopkins University. Data was analyzed with 
Logrank tests to give equal weight to each death time as no previous information 
suggested unequal distribution. Given more information about the physiology and 
estimated survival times for mice undergoing acute cardiotoxicity, another similar but 
modified test weighting death times accordingly, such as the Gehan-Wilcoxon or Peto-
Peto, could have produced more tailored and meaningful results. It is likely that the 
increased percent survival on day 19 ofthe study as seen in the mice at the University of 
Redlands as compared to the Johns Hopkins colony is due in fact to the presence of 
longer living female mice and not to some environmentally protective effect. 
The addition of females and mice of other backgrounds provided new insight into 
doxorubicin reactions over a more diverse population. While background survival trends 
were relatively consistent, female mice were seen to survive significantly longer than 
their male counterparts, a trend which seems to be reversed from the human population 
(Gharib & Burnett, 2002; Lipshultz et al., 1995; Minotti et al., 2004). Trend differences 
between humans and mice could be compounded by the multitude of demographic and 
health factors surrounding human studies, including type of cancer treated, baseline 
health, previous doses of anthracyclines, and other environmental factors. Many of the 
clinical trials and retrospective studies observing doxorubicin dosage and reaction utilize 
breast or ovarian cancer studies in women, making comparisons across the sexes 
especially difficult to control (Onda et al., 2004; Passardi et al., 2006; Swain et al., 2002; 
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Li & Gwilt, 2003). Despite these obstacles, studies that have observed populations of 
both sexes, having controlled for both cancer type and general health, still see the female 
sex as a risk factor in long term cardiotoxicity (Gharib & Burnett, 2002; Lipshultz et al. , 
1995). 
Another confounding trend revealed in our research was the increase and 
subsequent decrease in median survival over the period of the study. It would be expected 
that median survival should remain roughly stable as mice were treated in litter batches 
and as such were fairly controlled for sex and genotype. The distinct variation in survival 
would support the theory of a transient infection or other environmental factor affecting 
the colony. However, transient infection should, in theory, cause an opposite trend of 
decreased survival during the infection followed by an increase in survival once the 
infection had cleared. 
Necropsy reports confirmed the colony had a mild infection of pinworms. This is 
a significant difference from the initial study population at Johns Hopkins, which was 
maintained in a pathogen free colony and consistently received clean quarterly reports 
(Olson et al., 2003; Olson, L. personal communication). It is unlikely that the pinworms 
alone are responsible for the loss of protection in Cbr 1 +I- mice given the high prevalence 
of pinworms in approximately 75% of colonies across the nation, even pathogen free 
ones (Sueta et al. , 2002; Carty et al. , 2008). However, they could certainly be a 
contributing factor, considering that doxorubicin is well documented to compromise the 
immune system and could make the difference between an asymptomatic infection and a 
detrimental one (Khan et al., 2005; Singal & Iliskovic, 1998; Passardi et al. , 2006; Popov 
et al. , 2000; Onda et al. , 2004). Pinworms might also indirectly affect the immune system 
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response as they have been shown to produce significant differences in blood 
composition both at the bone marrow and peripheral level, including a decrease in 
neutrophilic granulocytes and monocytes, as well as an increase in eosinophils. Still other 
studies suggest that pinworm burden and the resulting physiological response may differ 
by sex, with males bearing heavier infections, confounding yet another aspect of our 
study (Bugarski et al., 2006; Suckow et al., 2001 ). 
While the necropsy reports were informative in identifying subclinical pathogens 
in the present colony, the sentinel mice were tested 2 years after the study had ended, and 
nearly 5 years after the study began. While it is hoped that any infection present during 
the study would have infected the sentinel mice, it is possible that a transient infection 
could have come and gone between times, and thus have been undetected in the sentinel 
results. In addition, other environmental factors, transient or permanent, could have had 
an impact on the non-sterile colony through the water, food, or air sources. Previous 
experiments have shown flavonoids, drugs such as B-napthoflavone, dexamethazone, and 
clotrimazole and other naturally occurring compounds can interact with promoter regions 
and alter regulation of reducing enzymes like Cbrl (Lakhman et al., 2007; Gonzales-
Covarrubias et al., 2008). Due to the non-sterile environment of the University of 
Redlands ' animal colony, these factors could reasonably be present and have an affect on 
the study population. Such temporary alterations in the colony would also call into 
question the protein levels in mice used for western blotting, since they were also 
sacrificed two years after the study ended. 
As no association could be identified between lineage and survival time, the 
theory that a genetic mutation had caused divergence in survival times between colonies 
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was refuted. Background was also ruled out as a major factor in survival time, providing 
confirmation that doxorubicin's effects seem to be replicable across a variety of genetic 
backgrounds. Such confirmation is fortuitous and should not be taken for granted as 
many phenotypes present varying expressivity depending on the underlying genetic 
background (Nadeau, 2001). If reducing Cbrl can be shown to be a viable supplement to 
doxorubicin treatment regimes, it would be hoped that the consistency across diverse 
genetic backgrounds would continue in the human population, decreasing cardiotoxicity 
in the majority of the treated population. 
This retrospective analysis was very limited due to its reliance on the assumption 
that any novel mutation was presented as a phenotype of decreased survival. Without 
carcasses or DNA samples, there was no way of further identifying any suspected 
mutation or of ultimately determining its inheritance pattern. However, the ruling out of 
possible outliers or unique trends within the sample population made it a valuable and 
necessary procedure in controlling for differences between the Johns Hopkins' and 
University ofRedlands' colonies. 
Western blotting confirmed that Cbrl+/- mice continue to express Cbrl at 
approximately the same levels in the liver and kidney, and nearly exactly the same in the 
heart as they did 5 years ago at Johns Hopkins. This negates the theory that Cbr 1 loss on 
the genomic level could have been masked by compensation mechanisms at the 
transcriptional level. Slight differences in kidney and liver expression comparing the 
Cbrl+l- mice to the WT mice were most likely due to the extreme expression level 
differences between males and females. To date, no expression level data has been 
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available on sex differences in Cbr 1 expression levels, making the extreme findings 
particularly notable. 
In general, males expressed less Cbr 1 than females in every organ except the 
spleen and heart, and these levels were only elevated about 10%. It seems unlikely that a 
10% increase in male heart Cbr1 expression as compared to females, with a sample size 
of eight mice, would be sufficient to cause the overwhelming increase in female survival 
as compared to male mice that was present in the study. The unlikelihood is supported 
by the fact that male expression levels in the two other organs known for Cbr 1 
expression, the liver and the kidney, were decreased to 58.7% and 0.16% ofthe female 
population, respectively. We would expect increased Cbr1 expression in the liver to be 
particularly detrimental to heart health as Cbr1 is a major reducing enzyme in the liver 
and would certainly contribute to the conversion of doxorubicin to doxorubicinol 
(Kassner et al., 2008). It is unknown what effects the metabolism of doxorubicin in other 
regions of the body have on cardiotoxicity, but presumably such underlying expression 
differences are evidence of widely differing physiology between sexes. Thus it is not 
surprising that our findings show males and females reacting very differently to 
doxorubicin, although it is opposite of what was expected based upon the metabolic 
hypothesis. 
Cbr 1 expression levels in the spleen, muscle, brain, and lung were comparable to 
previous research which has shown the mRNA and protein levels in these organs to be 
significantly lower than that of the liver and kidney (Kassner et al. , 2008; Miura et al. , 
2008). Lung expression level was too low to be seen, which was unexpected because 
previous experiments have shown slightly higher mRNA and protein levels in the lung as 
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compared to areas such as the brain (Kassner et al., 2008; Miura et al., 2008). Expression 
levels of the Cbr 1+1- mice relative to WT mice were particularly interesting in the brain 
and muscle as the expression was 225.8% and 166.9% that ofWT mice, respectively. 
Without knowing the individual variation among mice, expression level differences could 
be due to the small sample size or to a compensation mechanism in these organs to raise 
Cbr 1 levels at the transcriptional level. It is unknown why Cbr 1 would play such an 
important role as to require compensation in these particular organs if the latter is indeed 
the case. 
Of notable interest is the presence of extra banding in the 1 00 kDa range. 
Previous papers have also seen a characteristic double banding pattern, but have 
presented varying explanations (Krook et al., 1993; Wermuth et al., 1993; Iwata et al. , 
1990; Miura et al., 2008). Although the Cbr1 monoclonal antibody is also known to bind 
to the structurally similar carbonyl reductase 3 (Cbr3), previous papers have described 
Cbr3 as having a molecular weight of approximately 40 kDa, a difference of at least 60 
kDa from our unidentified band (Miura et al., 2008). It has also been suggested that Cbrl 
has the ability to autocatalytically modify its 239th residue, a lysine, so that its molecular 
mass becomes 35 kDa (Miura et al., 2008; Iwata et al. , 1993; Wermuth et al., 1993). All 
of the extra bands previously seen by others had significantly lower molecular weights 
than those present on the western blots of this study, so it was concluded that the heavier 
bands present were neither a modified form ofCbr1 nor its evolutionarily conserved 
sister protein, Cbr3. Consequently, they were ignored for the purposes of this study and 
attributed to either another reductase protein or an artifact ofblotting. However, further 
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experiments to identify the extraneous band might reveal another doxorubicin 
metabolizing enzyme. 
Also notable was the slightly uneven molecular weight of the Cbrl proteins 
within the organs studied. While all Cbrl bands fell between the 30 and 45 kDa 
molecular weight markers and all bands within one organ were consistent between mice, 
the band for the muscle fell closer to 45 kDa while the spleen, liver, and brain fell closer 
to the 30 kDa weight marker. It is conceivable that the majority of Cbr1 in some organs is 
catalytically modified and left unaltered in others (Miura et al. , 2008; Iwata et al., 1993; 
Wermuth et al., 1993 ). It is also important to note that among previous research there is a 
slight discrepancy in the molecular weight of Cbrl , with some papers placing it at 30 kDa 
while others report 35 kDa or 33kDa (Miura et al., 2008; Uniprot 2009; Iwata et al., 
1990). 
Histological analysis failed to find an association between survival and heart 
health, a difference from the earlier study conducted at Johns Hopkins (Olson et al. , 
2003). Suprisingly, the weight ofthe hearts seemed to better correlate with survival time, 
although the sample size was too small to show significance. Further analysis of heart 
weight would be illuminating, but male and female samples would need to be separated 
as males are expected to have larger hearts corresponding to their larger body weights. 
Our method of quantifying heart health based upon multiple, quantitative factors has the 
definite advantage of being repeatable regardless of researcher as compared to the more 
traditional Billingham scale (Billingham et al., 1991). Although Olson et al. (2003) saw a 
clear difference between the grossly healthy Cbr 1 +I- hearts and the completely 
cardiotoxic WT hearts, the additional spotty toxicity observed in this study has also been 
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previously recorded as a telltale sign of doxorubicin induced toxicity in human 
populations (Olson et al., 2003; Cotran et al., 1999). 
Because the mice's survival appears not to be dependent upon heart health, it is 
assumed that some other factor is causing premature death. Experimentation has already 
been conducted to rule out protein expression alteration, pathogenic infection, or genetic 
predisposition, supporting the theory that some other doxorubicin induced toxicity is 
responsible for mouse death. Two of the most common and acute toxicities reported in 
human trials include gastrointestinal toxicity and leukopenia (Onda et al., 2004; Passardi 
et al., 2006; Popov et al., 2000). In one study, leukopenia and neutropenia were so severe 
as to be dose limiting to four out of five patients at the lowest dosage of 20mg/m2 (Onda 
et al., 2004). Fortunately, drugs such as granulocyte colony-stimulating factor (G-CSF) 
are readily available to recover some of the blood cell loss caused by the chemotherapy in 
human trials (Onda et al., 2004). It is therefore not unreasonable to conclude that acute 
leukopenia was responsible for mouse death following a bolus dose of doxorubicin, either 
alone or in conjunction with some subclinical factor not present at the sterile Johns 
Hopkins facility. 
The discrepancy between male and female survival may also be explained by this 
theory as other studies have documented that human females have higher baseline levels 
ofneutrophils than males (Bain & England 1975). If this phenomenon is conserved in 
mice, female mice may have a blood cell buffer providing them with stronger immune 
responses to any interfering environmental factors. This would be supported by our data 
of longer survival time in female mice. However, this still leaves the reversed human 
trend of females experiencing a worse reaction to doxorubicin unexplained: if female 
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mice have higher survival rates than males due to their neutrophil counts, it would 
presumably hold true for humans as well (Gharib & Burnett, 2002; Lipshultz et al., 1995; 
Minotti et al., 2004). Resulting discrepancies could be explained by the bolus dosage of 
doxorubicin given to the mice as compared to the smaller and more spread out doses 
generally given to humans, as well as the human cancers being treated as compared to the 
otherwise healthy mice. Because breast cancer is one of the most common cancers treated 
with doxorubicin, the discrepancy of male versus female prevalence makes controlling 
for such factors difficult. 
One of the major limitations of this experiment was the fact that only the hearts of 
the mice were saved for later examination, making retrospective studies involving 
toxicity levels of the blood or other organs impossible. Also, mouse hearts were ideally 
collected immediately after death. Practically, this was the case when mice were 
sacrificed due to quality of life issues, but not the case for mice found dead. Thus the 
hearts coming from mice found dead could have significant effects on tissue quality not 
related to toxicity. Future studies would benefit from a finer hematoxylin filter to 
effectively remove all crystallization and to minimize staining artifacts on the slides. 
Additional research measuring blood cell counts and other acute, alternate 
toxicities in doxorubicin treated mice could identify the unknown cause of death in this 
study. Alternately, the experiment could be repeated, supplementing the mice with the 
granulocyte colony-stimulating factor (G-CSF) to see if the cardioprotection observed 
with decreased Cbrl expression levels returns when manageable and temporary toxicities 
are controlled for. It would also be illuminating to observe survival for longer than 19 
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days to see if female mice survive indefinitely, or if they merely have a longer survival 
time. 
Although this particular study was unable to associate Cbrl expression levels and 
cardiotoxicity due to unexpected factors affecting survival, research continues to explore 
the connection between Cbrl and doxorubicin. More recently, studies have shown that 
Cbr3 is not only expressed, but is also a functional enzyme. Reports vary as to whether 
Cbr3 shares the same metabolites as Cbrl, and whether it could also have an impact on 
doxorubicin, thereby complicating the one enzyme model which dominates current 
thought (Miura et al., 2008). Other studies are taking a more genetic route, observing 
single nucleotide polymorphisms (SNPs) present in both Cbrl and Cbr3 and studying 
their affect on the enzymes' metabolic capabilities (Gonzales-Covarrubias et al., 2007; 
Lakhman et al., 2007; Miura et al., 2008). If SNPs decreasing doxorubicin metabolism 
can be found in the human population, these individuals might have a naturally protected 
heart and thus be candidates for larger doses, whereas individuals with SNPs increasing 
doxorubicin metabolism might wish to consider a decreased doxorubicin dosage or 
simply finding alternative chemotherapy options. Further genetically focused research is 
also being conducted to observe the consequences of doxorubicin on cellular expression 
using microarrays (Kudoh et al., 2000). Learning more about which genes are up or down 
regulated in the presence of doxorubicin could lead to a better overall understanding of 
the exact mechanism behind cardiotoxicity, about which little is currently known. 
If further studies revealed that the cardioprotection had been masked by other 
factors, the long term goal of creating a Cbrl inhibitor for human trials would still be 
supported. Ultimately, this study suggests that the one enzyme metabolic hypothesis and 
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the physiology behind toxicity are more complicated than previously thought, but it does 
not rule out the benefits of decreasing Cbr1 clinically to protect human patients during 
doxorubicin chemotherapy. 
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